JPWO2021023811A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021023811A5 JPWO2021023811A5 JP2022502090A JP2022502090A JPWO2021023811A5 JP WO2021023811 A5 JPWO2021023811 A5 JP WO2021023811A5 JP 2022502090 A JP2022502090 A JP 2022502090A JP 2022502090 A JP2022502090 A JP 2022502090A JP WO2021023811 A5 JPWO2021023811 A5 JP WO2021023811A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- solid pharmaceutical
- composition according
- dapagliflozin
- lubricant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19190623 | 2019-08-07 | ||
| EP19190623.9 | 2019-08-07 | ||
| EP20172415.0 | 2020-04-30 | ||
| EP20172415 | 2020-04-30 | ||
| PCT/EP2020/072106 WO2021023811A1 (fr) | 2019-08-07 | 2020-08-06 | Compositions solides comprenant un agoniste de glp-1, un inhibiteur de sglt2 et un sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022545156A JP2022545156A (ja) | 2022-10-26 |
| JPWO2021023811A5 true JPWO2021023811A5 (fr) | 2023-07-13 |
Family
ID=71894842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022502090A Withdrawn JP2022545156A (ja) | 2019-08-07 | 2020-08-06 | Ｇｌｐ－１作動薬と、ｓｇｌｔ２阻害剤と、ｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固形組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220265777A1 (fr) |
| EP (1) | EP4009941A1 (fr) |
| JP (1) | JP2022545156A (fr) |
| KR (1) | KR20220044269A (fr) |
| CN (1) | CN114173766A (fr) |
| AU (1) | AU2020325708A1 (fr) |
| BR (1) | BR112022000490A2 (fr) |
| CA (1) | CA3144611A1 (fr) |
| CL (1) | CL2022000137A1 (fr) |
| CO (1) | CO2022000578A2 (fr) |
| IL (1) | IL289504A (fr) |
| MX (1) | MX2022000827A (fr) |
| PE (1) | PE20220751A1 (fr) |
| TW (1) | TW202114730A (fr) |
| WO (1) | WO2021023811A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI797133B (zh) * | 2017-06-09 | 2023-04-01 | 丹麥商諾佛 儂迪克股份有限公司 | 用於經口投予的固體組成物 |
| PE20210453A1 (es) * | 2018-02-02 | 2021-03-08 | Novo Nordisk As | Composiciones solidas que comprenden un agonista de glp-1, una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico y un lubricante |
| CN117580583A (zh) * | 2021-06-25 | 2024-02-20 | 甘李药业股份有限公司 | Pcsk9抑制剂和glp-1受体激动剂的药物组合 |
| WO2023065231A1 (fr) * | 2021-10-21 | 2023-04-27 | Guangzhou Dazhou Biomedicine Ltd. | Administration orale d'agents thérapeutiques |
| CN114085203A (zh) * | 2021-12-17 | 2022-02-25 | 宁波高新区美诺华医药创新研究院有限公司 | 达格列净组合物 |
| WO2023123063A1 (fr) * | 2021-12-29 | 2023-07-06 | Guangzhou Dazhou Biomedicine Ltd. | Administration orale |
| CN116370609B (zh) * | 2023-06-01 | 2023-08-15 | 北京普诺旺康医药科技有限公司 | 包含血管活性肠肽和吸收增强剂的固体组合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130035281A1 (en) * | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN105503802A (zh) * | 2016-01-15 | 2016-04-20 | 中山大学 | 一种达格列净-柠檬酸共晶的制备方法 |
| WO2018124497A1 (fr) * | 2016-12-30 | 2018-07-05 | 한미약품 주식회사 | Préparation compisite pharmaceutique contenant de la dapagliflozine l-proline et un agent antidiabétique |
| TWI797133B (zh) * | 2017-06-09 | 2023-04-01 | 丹麥商諾佛 儂迪克股份有限公司 | 用於經口投予的固體組成物 |
-
2020
- 2020-08-06 CA CA3144611A patent/CA3144611A1/fr not_active Withdrawn
- 2020-08-06 TW TW109126705A patent/TW202114730A/zh unknown
- 2020-08-06 EP EP20749915.3A patent/EP4009941A1/fr not_active Withdrawn
- 2020-08-06 JP JP2022502090A patent/JP2022545156A/ja not_active Withdrawn
- 2020-08-06 CN CN202080055403.XA patent/CN114173766A/zh not_active Withdrawn
- 2020-08-06 MX MX2022000827A patent/MX2022000827A/es unknown
- 2020-08-06 WO PCT/EP2020/072106 patent/WO2021023811A1/fr unknown
- 2020-08-06 KR KR1020227001918A patent/KR20220044269A/ko unknown
- 2020-08-06 BR BR112022000490A patent/BR112022000490A2/pt not_active Application Discontinuation
- 2020-08-06 US US17/628,459 patent/US20220265777A1/en not_active Abandoned
- 2020-08-06 PE PE2022000109A patent/PE20220751A1/es unknown
- 2020-08-06 AU AU2020325708A patent/AU2020325708A1/en not_active Withdrawn
-
2021
- 2021-12-29 IL IL289504A patent/IL289504A/en unknown
-
2022
- 2022-01-20 CL CL2022000137A patent/CL2022000137A1/es unknown
- 2022-01-24 CO CONC2022/0000578A patent/CO2022000578A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4077320B2 (ja) | ５−メチル−１−フェニル−２−（１ｈ）−ピリドンを有効成分として含有する医薬製剤 | |
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| US20140336148A1 (en) | Combinations of diacerein and non-steroidal inflammation drugs | |
| JP5403935B2 (ja) | 経口用の慢性疼痛予防または治療剤 | |
| JP5542309B2 (ja) | 経口医薬組成物 | |
| JP5828609B2 (ja) | 持続性解熱鎮痛消炎剤 | |
| US9561204B2 (en) | Effervescent compositions containing N-acetylcysteine | |
| JPWO2021023811A5 (fr) | ||
| JP5134802B2 (ja) | 塩酸ブロムヘキシン含有量低下の防止方法 | |
| EP2959891A1 (fr) | Compositions pharmaceutiques à libération modifiée de sofosbuvir et ribavirine | |
| JP6100510B2 (ja) | 抗感冒剤 | |
| US11364261B2 (en) | Alleviating common cold and influenza symptoms with molecular hydrogen | |
| JP2021066751A (ja) | 経口用医薬組成物 | |
| JP6280303B2 (ja) | 感冒薬組成物 | |
| JP6073231B2 (ja) | 安定な医薬組成物 | |
| RU2432942C1 (ru) | Композиция для приготовления обладающей пролонгированным действием лекарственной формы для лечения орофарингеальной зоны | |
| ES2952013T3 (es) | Combinación de ibuprofeno y tramadol para aliviar el dolor | |
| RU2780252C1 (ru) | Фармацевтическая композиция для лечения вирусных заболеваний | |
| JP2018076312A (ja) | アセトアミノフェン、イソプロピルアンチピリン及びショウガ由来成分を含有する医薬組成物 | |
| JP7355846B2 (ja) | 固形製剤 | |
| JPH059116A (ja) | ３−オキシゲルミルプロピオン酸組成物並びに該組成物を主成分とする細胞変性抑制剤 | |
| EP2146713B1 (fr) | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens | |
| JP6804190B2 (ja) | 医薬組成物 | |
| WO2015197549A1 (fr) | Nouvelle composition pharmaceutique de sofosbuvir et de ribavirine | |
| JP2024503490A (ja) | シロスタゾールを含む組成物の脳血管疾患への応用 |